Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

abiraterone acetate

- PMLiVE

NICE backtracks on Gazyvaro rejection

Roche agrees to patient access scheme to help gain leukaemia recommendation

- PMLiVE

Succinct and ecancer team up on oncology education events

Will work together to support HCPs

- PMLiVE

AZ and Cancer Research UK to collaborate on new medicines

Charity’s scientists to be given access to pharma company’s molecule library

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

- PMLiVE

AZ seeks leg up in antiplatelet market with Brilinta antidote

Reversal agent has been developed by company's biotech subsidiary Medimmune

- PMLiVE

AZ says cancer will be ‘sixth growth platform’

Firm currently has 14 drugs in phase III trials

- PMLiVE

NHS names drugs to be re-evaluated for Cancer Drugs Fund

Will assess cost-effectiveness of drugs including Kadcyla and Avastin

- PMLiVE

FDA approves Olysio/Sovaldi combination in hep C

Janssen drug recommended for use along with Gilead’s blockbuster

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

- PMLiVE

Nexium windfall lifts AZ in third quarter

Still to feel effects of generic competition

- PMLiVE

AZ advances immuno-oncology ambitions

Buys imaging company and signs PD-1 collaborations with Pharmacyclics and J&J

- PMLiVE

AZ to work with UK university on drug delivery technologies

Company's staff will also teach parts of courses at The University of Manchester

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links